Genotypes and Transmitted Drug Resistance among Treatment-Naive HIV-1-Infected Patients in a Northwestern Province, China: Trends from 2003 to 2013

Ke Zhao1*, Wenzhen Kang1*, Qingquan Liu2, Yuan Li1, Qing Liu1, Wei Jiang1, Yan Zhuang1, Zisheng Guo1, Zhuoran Yu1, Xinhong Li1, Chunfu Wang1, Na Yao1, Yongtao Sun1*

1 Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi Province, China, 2 Department of Endocrinology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi Province, China

Abstract

Background: Transmitted drug resistance (TDR) reduces the efficacy of initial antiretroviral treatment and has become a public health concern. Little information is available regarding the genetic diversity of HIV-1 and the prevalence of TDR among treatment-naive patients in a northwestern province of China since the implementation of national free antiretroviral therapy (ART).

Methods: Blood samples from 372 HIV-1 treatment-naive patients were collected between 2003 and 2013 in Shaanxi province. Viral RNA was extracted for nested PCR, and phylogenetic reconstruction and recombination analyses were performed to characterize patterns of the HIV-1 subtypes. Genotypic drug resistance testing was performed using an in-house assay to determine trends in the prevalence of HIV-1 transmitted drug resistance.

Results: Multiple genotypes were identified among the patients in Shaanxi, including B (25.0%), C (0.3%), G (0.3%), and CRF01_AE (39.2%), CRF07_BC (32.7%), CRF08_BC (0.8%), CRF55_01B (1.1%), and CRFs (0.6%). The subtypes were associated with the transmission routes ($\chi^2 = 77.113, p < 0.01$). In this study, a low baseline CD4+ T cell count and a high viral load were found among CRF01_AE-infected patients compared with patients who were infected with non-CRF01_AE ($p < 0.01$) through sexual transmission; however, the CRF01_AE subtype was not associated with a low baseline CD4+ T cell count or a high viral load in Chinese patients infected through blood transmission ($p = 0.249$). The overall TDR rate in this population was 4.4% between 2003 and 2013. A univariate logistic regression model revealed that a low CD4+ T cell count ($\leq 100$ cells/$\mu$L) was associated with the development of drug-resistant strains.

Conclusion: Our work revealed diverse HIV-1 subtype distributions in Shaanxi province. We identified a low and stable TDR time trend among ART-naive patients. These findings enhance our understanding of HIV-1 genetic diversity and provide some guidelines for the improvement and implementation of a comprehensive public health strategy of HIV-1 TDR prevention.

Introduction

Highly active antiretroviral therapy (HAART) has dramatically decreased the morbidity and mortality caused by HIV-1. According to the 2013 UNAIDS report, an estimated 35.3 million (range, 32.2–38.8 million) people were infected with HIV globally in 2012. The number of newly acquired HIV infections was 2.3 million (range, 1.9–2.7 million), showing a 33% decline in the number of new infections from 3.4 (3.1–3.7) million in 2001. The number of AIDS deaths is also declining, with 1.6 (1.4–1.9) million deaths in 2012, down from 2.3 (2.1–2.6) million deaths in 2005 [1]. Despite these achievements, HAART is not able to eliminate infected cells, and plasma viremia generally rebounds quickly after treatment is discontinued [2–3]. A safe and efficacious HIV-1 vaccine is essential for controlling the pandemic and eradicating HIV-1 infection [4]. However, the vaccine development attempts have been disappointing so far, and there is a lack of broad and potent protective neutralizing antibodies [5–6]. One of the greatest challenges in vaccine design is the rapidly evolving genetic...
diversity of HIV-1. As a result, monitoring the genetic diversity of 
HIV-1 is very important for understanding the molecular 
epidemiology and controlling the spread of the HIV-1 epidemic. 

Different HIV-1 subtypes have distinct regional distribution 
patterns in China. CRF08_BC was found to be dominant in 
Yunnan province, CRF01_AE was dominant in Guangxi prov-
cince, and subtype B (especially Thai-B) was dominant in Henan 
province [7]. Shaanxi province is located in the northwestern 
region of China, and it has a low prevalence of HIV-1 compared 
with the other provinces; However, the proportion of patients 
infected via MSM has been increasing rapidly each year. The 
HIV/AIDS epidemic has presented novel characteristics; How-
ever, comprehensive analyses on the viral genotypes in Shaanxi 
remain markedly limited.

Drug-resistant HIV-1 strains could be transmitted from one 
individual to another. Due to such transmitted drug resistance 
(TDR), a newly infected patient might carry a drug-resistant virus 
even if he or she has not yet used antiretroviral drugs. The 
expansion of antiretroviral treatment programs have led to 
increasing concern about the development of TDR. Available 
data revealed that between 10% and 17% of ART-naı¨ve patients 
in Europe, the United States, Japan, and Australia have drug 
resistance to at least one antiretroviral drug [8–10]. A previous 
survey performed between 2004 and 2005 demonstrated that the 
rate of TDR was relatively low (3.8%) in China compared with the 
rate in developed countries [11]. However, the effect of TDR 
might be higher in patients in China than in patients in developed 
countries because in China, viral genotyping is typically unavail-
able, and transmitted resistance is rarely detected. Insufficiently 
strong drugs would be less effective in reducing the viral load, 
which could lead to the development of multi-class drug resistance. 
In addition, fewer first- or second-line treatment options are 
available for patients in China. Thus, surveillance data about the 
prevalence of TDR based on a large population over time are 
necessary to develop a rational public health strategy. HIV-1 TDR 
data from China are increasingly available. For example, a recent 
study revealed that the prevalence of TDR from 2007 to 2010 was 
1.3% in Chengdu [12], and an overall 4.9% TDR rate was found 
among ART-naive MSM in 19 provinces/cities in 2012 [13].

| Primer name | Sequence (5’-3’) | Location | Purpose |
|-------------|------------------|----------|---------|
| MAW 26*     | TGGAAATGTTGAAAGGAAGGAC | 2028-2050 | one-step RT-PCR |
| RT21*       | CTTGATTTCTGCTTTA1AATGCTTTTATGGG | 3539-3509 | one-step RT-PCR |
| PRO-1*      | CAGAGCACCAGCCCCACCA | 2147-2166 | Second-round PCR |
| RT20*       | CTTGCAATTCTGTACCTGCCTC | 3462-3441 | Second-round PCR |
| MAW26-07BCb | TGGAAATGTTGAAAGGAAGGAC | 2029-2050 | one-step RT-PCR |
| RT21-07BCb  | CTTGATTTCTGCTTTA1AATGCTTTTATGGG | 3539-3509 | one-step RT-PCR |
| PRO1-07BCb  | CAGAGCACCAGCCCCACCA | 2147-2166 | Second-round PCR |
| RT20-07BCb  | CTTGCAATTCTGTACCTGCCTC | 3462-3441 | Second-round PCR |
| MAW26-01AEc | TGGAAATGTTGAAAGGAAGGAC | 2029-2050 | one-step RT-PCR |
| RT21-01AEc  | CTTGATTTCTGCTTTA1AATGCTTTTATGGG | 3539-3509 | one-step RT-PCR |
| PRO1-01AEc  | CAGAGCACCAGCCCCACCA | 2147-2166 | Second-round PCR and Reverse sequencing |
| RT20-01AEc  | CTTGCAATTCTGTACCTGCCTC | 3462-3441 | Second-round PCR and Forward sequencing |
| S1          | GGACCTACACCTGTCACA | 2484-2501 | Forward sequencing |
| S2          | GCTGGTTGTTGATTTCC | 2842-2826 | Reverse sequencing |
| S3          | CCTGATATAAACATAGGACAC | 2946-2967 | Forward sequencing |

Primer c was preferred, Primer a or b was alternative. 

Table 2. The List of primers used in Bootscanning analysis.

| Primer name | Sequence (5’-3’) | Location | Purpose |
|-------------|------------------|----------|---------|
| PG3         | AGGGACTTGAAAGCGAAAG | 648-666 | one-step RT-PCR |
| RT21        | CTTGATTTCTGCTTTA1AATGCTTTTATGGG | 3539-3509 | one-step RT-PCR |
| gag-F2      | ATGGGTGCGAGAGCGTCARTATTAA | 790-814 | Second-round PCR |
| RT20        | CTTGCAATTCTGTACCTGCCTC | 3462-3441 | Second-round PCR |
| POL-1       | TGGAAATGTTGAAAGGAAGGAC | 2029-2050 | one-step RT-PCR |
| POL-2       | CTTGATTTCTGCTTTA1AATGCTTTTATGGG | 3539-3509 | one-step RT-PCR |
| POL-3       | CAGAGCACCAGCCCCACCA | 2147-2166 | Second-round PCR |
| POL-4       | CTTGCAATTCTGTACCTGCCTC | 3462-3441 | Second-round PCR |

doi:10.1371/journal.pone.0109821.t001

doi:10.1371/journal.pone.0109821.t002
However, very few genetic studies have been performed on HIV-1 TDR in Shaanxi province. In the present study, to assess the prevalence of transmitted drug resistance and identify the pattern of circulating subtypes among HAART-naive patients, plasma specimens from 372 HIV-1 treatment-naive patients were collected between 2003 and 2013. Viral RNA was extracted for nested PCR, and phylogenetic reconstruction and recombination analyses were performed to characterize the patterns of the HIV-1 subtypes. Genotypic drug resistance testing was conducted using an in-house assay to determine trends in the prevalence of HIV-1 transmitted drug resistance among HIV-1 infected individuals in Shaanxi province.

### Table 3. The baseline characteristics of the study population.

| Total | 364 | Percentage |
|-------|-----|------------|
| **Gender** | | |
| Male | 304 | 83.5% |
| Female | 60 | 16.5% |
| Age | | |
| ≤25 | 75 | 20.7% |
| 26–35 | 130 | 35.7% |
| 36–45 | 93 | 25.5% |
| >45 | 66 | 18.1% |
| **Transmission routes** | | |
| Heterosexual contact | 104 | 28.6% |
| Homosexual contact | 177 | 48.6% |
| Blood transmission | 49 | 13.5% |
| Intravenous drug injection | 14 | 3.8% |
| Unknown | 20 | 5.5% |
| **CD4⁺ T Count (cells/ul)** | | |
| ≤100 | 109 | 29.9% |
| 101–200 | 44 | 12.1% |
| 201–350 | 92 | 25.3% |
| 351–500 | 69 | 19.0% |
| >500 | 50 | 13.7% |
| **HIV viral load (copies/ml)** | 364 | |
| ≤1000 | 34 | 9.3% |
| 1001–10000 | 54 | 14.8% |
| 10001–100000 | 105 | 28.9% |
| 100001–1000000 | 132 | 36.3% |
| >1000000 | 39 | 10.7% |
| **Year of HIV diagnosis** | | |
| 2003–2005 | 41 | 11.3% |
| 2006–2008 | 36 | 9.9% |
| 2009–2011 | 122 | 33.5% |
| 2012–2013 | 165 | 45.3% |
| **HIV-1 subtype** | | |
| CRF01_AE | 143 | 39.2% |
| CRF07_BC | 119 | 32.7% |
| B | 91 | 25.0% |
| CRF55_01B | 4 | 1.1% |
| CRF08_BC | 3 | 0.8% |
| URF(CRF01_AE/07_BC) | 2 | 0.6% |
| C | 1 | 0.3% |
| G | 1 | 0.3% |

URFs, unique recombinant forms; CRFs, circulating recombinant forms.
doi:10.1371/journal.pone.0109821.t003
Materials and Methods

Study Subjects

A total of 372 newly diagnosed HIV-1-positive patients who visited the infectious diseases clinic in Tangdu hospital from January 2003 to December 2013 were enrolled in the study. The department of infectious diseases in Tangdu hospital is the main HIV/AIDS clinic in Shaanxi province. This clinic is responsible for HIV intervention and prevention programs, and provides free ART with care in Shaanxi province. HIV-1 infection status was determined by an Enzyme-Linked Immunosorbent Assay (ELISA, Livzon, China) and confirmed by Western blot assay (HIV BLOT 2.2, MP Diagnostics, Singapore). Inclusion criteria for this study were age 18–75 years, both genders, antiretroviral-naïve, newly diagnosed and willingness to sign informed consent. The main exclusion criteria were pregnancy or breastfeeding, anticipated poor adherence.

Ethics Statement

This study was reviewed and approved by the institutional review board of the Fourth Military Medical University in Xi’an, Shaanxi, China. Written informed consent was obtained from every participant before blood sample donation.

Figure 1. Phylogenetic tree analysis from ART-naïve patients diagnosed between 2003–2008. 77 sequences of HIV-1 gag-pol (1057 bp) were used and each reference sequence is labeled with the HIV-1 subtype, followed by country, year, sampling name, and accession number. The trees were constructed by the neighbor-joining method. Bootstrap values were calculated from 1,000 analyses, and bootstrap probabilities greater than 70% are indicated at the corresponding nodes of the tree. Open circle: homosexual contact, solid circle: heterosexual contact, open square: blood transmission, solid square: IDU, open triangle: unknown. doi:10.1371/journal.pone.0109821.g001
Plasma HIV-1 RNA assay and CD4⁺ T-cell count

The HIV-1 viral load was determined using real-time reverse-transcription and polymerase chain reaction (RT-PCR) using a Cobas TaqMan 48 HIV-1 test with the high pure system (COBAS TaqMan48, Amplink version 3.2; Roche Molecular Systems, Branchburg, NJ), as previously described [14]. CD4⁺ T cell counts were performed on a FACS Calibur (Becton Dickinson, San Jose, CA) using the TRITEST three-color CD4/CD8/CD3 reagent and TRUCOUNT tubes (Becton Dickinson, San Jose, CA) according to the manufacturer's instructions. The cells were analyzed with a multiset automatic analysis software program.
Amplification and sequencing of HIV-1 pol

The viral RNA was extracted from 140 μL of plasma with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Reverse transcription and first-round PCR were performed by one-step RT-PCR (Prime Script One Step RT-PCR Kit, Takara, Dalian, China). The RT-PCR and sequencing primers that were optimized based on previous reports [15] are shown in Table 1. The thermal cycling consisted of 50°C for 30 min and 94°C for 5 min, followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min. The final incubation was at 72°C for 10 min. The nested PCR was performed in a 50-μL reaction mixture; the cycling conditions were 94°C for 5 min, followed by 30 cycles of PCR at 94°C for 30 s, 63°C for 30 s, 72°C for 2.5 min, and an extension at 72°C for 10 min. The PCR product of 1315 bp in length contained a full-length protease (PR) gene of 99 amino acid codons and the first 299-codon segment of the reverse transcriptase (RT) gene. The PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and sequenced using an ABI 3730 automated sequencer followed by editing with SeqScape software v2.5 (Applied Biosystems, Foster City, CA).

Sequence analysis

The sequence contig assembly was performed using the analysis software, Sequencher 4.8b1 [Gene Codes Corporation, Ann Arbor, MI]. Transmitted HIV-1 drug resistance was defined as one or more mutations from the Surveillance Drug Resistance Mutations (SDRM) list recommended by the World Health Organization [16]. The mutations were interpreted by the Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm [http://sierra2.stanford.edu/sierra/servlet/JSierra] to predict the susceptibility of the viruses to antiretroviral drugs, and low level resistance or greater was reported.

HIV-1 Subtyping and Bootscanning analysis

The HIV-1 subtyping was performed by phylogenetic analyses of the pol sequences. The ClustalW Multiple Alignment [17] and manual editing were performed using BioEdit Sequence Alignment Editor (Ibis Biosciences, Carlsbad, CA) with HIV-1 reference sequences from the Los Alamos database [http://www.hiv.lanl.gov]. The phylogenetic trees were generated by the neighbor-joining method under the Kimura two-parameter mode (1,000 replicates) with MEGA5.05 [18].

To demonstrate possible intersubtype mosaicism, sequences that were not grouped with any regular HIV-1 subtype were again amplified for entire full-length gag-pol gene sequencing (790 bp-5221 bp on HXB2). Two sets of primers designed for the determination of gag-pol (790 bp-3462 bp on HXB2) and pol (2068 bp-5221 bp on HXB2) sequences are shown in Table 2. For the gag-pol gene amplification, the cloning conditions of one step RT-PCR in a 25 μL reaction were 50°C for 30 min, 94°C for 5 min, 32 cycles of 94°C for 45 s, 52°C for 45 s, and 72°C for 5 min, followed by an extension at 72°C for 10 min. The nested PCR in a 30-μL reaction had the same conditions as above. For the pol amplification, the one Step RT-PCR cycling conditions were 50°C for 30 min, 94°C for 2 min, followed by 3 cycles of 94°C for 30 s, 55°C for 1 min, and 72°C for 4 min, 32 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 3 min 30 s, and the final incubation was at 72°C for 10 min. The nested PCR cycling conditions were 94°C for 2 min, followed by 3 cycles of 94°C for 30 s, 62°C for 1 min, and 72°C for 4 min, 32 cycles of 94°C for 15 s, 62°C for 30 s, and 72°C for 3 min 30 s, and the final incubation was at 72°C for 10 min. The amplicons were directly sequenced using internal walking primers. The sequences were analyzed using the Recombination Identification Program (RIP, version 3.0; http://hiv-web.lanl.gov) [19], and the bootscanning analysis was performed using Simplot [SimPlot version 3.5.1; S. Ray, Johns Hopkins University, Baltimore, MD; http://sray.med. som.jhu.edu/RaySoft/SimPlot/][20]. The following parameters were used: window: 200 bp, step: 20 bp, gapstrip: on, replicates: 100, Kimura 2-parameter, T/c: 2.0, Neighbor-Joining.

Statistical analysis

The statistical analysis was conducted using the SPSS 17.0 package (SPSS Inc. Chicago, IL, USA). The figures were drawn using GraphPad Prism 5 (GraphPad Software, San Diego CA) and Origin 7.5 (OriginLab Corporation, Northampton, MA). The categorical variables were compared using the chi-squared test or Fisher’s exact test when appropriate, and two independent samples nonparametric tests (Mann-Whitney U) were used to compare the continuous data. A logistic regression analysis model was used to identify the factors associated with drug resistance. The factors with significant univariate P-values <0.1 were selected for inclusion in the multivariate model, which used a forward stepwise method. All of the statistical tests were 2-tailed (P<0.05).

Gene accession numbers

All of the sequences obtained in this study were submitted to GenBank with accession numbers KJ401414 to KJ401768, KJ364641 and KJ364642.

Results

Three hundred seventy-two HIV-1 confirmatory samples were collected in this study; all of the samples were successfully amplified. Eight (2.15%, 8/372) PCR products could not be sequenced, resulting in a final analysis of 364 samples from treatment-naïve, HIV-1 positive individuals in Shaanxi who newly diagnosed between 2003 and 2013. The baseline characteristics of the study population were shown in Table 3: 83.5% (304/364) of the patients were male, and the median age of the study group was 34 (IQR: 27–42) years. The median nadir CD4+ T cell count was 257 (IQR: 70–336) cells per microliter, and the median viral load was 4.94 log10 (IQR: 4.03–5.56) copies/ml. Although an HIV viral load of greater than 3 log copies/ml was traditionally presumed to be necessary for genotypic resistance testing [21], the samples with an HIV viral load of 1.94–7.88 log10 copies/ml were successfully amplified using optimizing primers. All of the patients were recruited within 6 months of diagnosis.
HIV-1 Variants

Three hundred sixty-four HIV-1 pol gene sequences (1057 bp) were subjected to subtype determination by phylogenetic tree analysis (Figure 1–3). One hundred forty-three (39.2%) CRF01_AE strains, one hundred and nineteen (32.7%) CRF07_BC strains, 91 (25.0%) subtype B strains, 3 (1.0%) CRF08_BC, 1 (0.27%) subtype G, and 1 (0.27%) subtype C were identified. Six isolates (kang007a, kang190, kang253, kang019as, kang140, and ztt0203) were not clustered with the basic reference subtypes/CRFs. Bootscanning analysis revealed that isolates ztt0203, kang007a, kang190, and kang253 were similar to a novel HIV-1 circulating recombinant form CRF55_01B, which is composed of CRF01_AE and subtype B, with four recombination breakpoints in the pol gene [22]. Bootscanning analysis revealed that two other isolates (kang019as and kang140) showed a recombinant CRF01_AE/07BC pol gene (Figure 4).

Over the past 10 years, the prevalence of the CRF01_AE subtype in patients increased from 9.76% to 43.03%. A similar trend was observed for subtype CRF07_BC infections, which accounted for 25.17% of all infections in the period 2003–2005 and increased during the last decade, reaching 41.21% in the years 2012–2013. During 2003–2005, subtype B infections accounted for 73.17% of all infections, and this decreased to 11.52% from 2012 to 2013 (Figure 5). Increasing HIV subtype diversity was found. Novel recombinant forms: CRF55_01B and URFs, were identified in the period 2012–2013.

HIV-1 transmission routes

The major transmission routes in the 364 patients were homosexual contact (48.6%) and heterosexual contact (28.6%), followed by blood transmission (13.5%), injection drug use (3.8%), and unknown (5.5%). Substantial changes in the transmission route occurred in the population of HIV-1 infected patients over time in Shaanxi province. The most important changes over the last decade were observed in the proportion of men who have sex with men (MSM). Before 2006, HIV-1 was spread mainly through blood and heterosexual contact transmission (36.10% and 29.27%, respectively). Between 2006 and 2008, the proportions of HIV-1 transmission through blood and homosexual contact were 25.56% and 27.78%, respectively. From the beginning of 2009, homosexual transmission of HIV displayed explosive growth and became the dominant route of HIV-1 transmission, accounting for 52.46% of the spread. In last time period (2012–13), homosexual transmission exceeded the other routes of HIV-1 transmission and further increased to 66.67% of the spread. The distribution of the routes of HIV-1 transmission in this region is shown in Figure 6. Subtypes were associated with the transmission route ($\chi^2 = 77.113$, $p < 0.01$). IDU was the main risk group for the spread of CRF01_AE ($\chi^2 = 116.42$, $p < 0.01$). Clade CRF01_AE was found significantly more frequently in homosexual patients than in the other risk groups ($\chi^2 = 169.552$, $P < 0.01$). Subtype B was found significantly more frequently in blood transmission patients than in the other risk groups ($\chi^2 = 31.247$, $P < 0.01$)

We classified HIV-1 infected individuals as CRF01_AE and non-CRF01_AE groups according to the subtypes. As shown in Figure 7-A, a low level baseline CD4$^+$ T cell count was found among the CRF01_AE-infected persons compared with the non-CRF01_AE patients infected through sexual transmission (homosexual contact and heterosexual contact) ($p = 0.027$ and $p = 0.005$, respectively); however, the CD4$^+$ T cell count was not lower...
compared with the non-CRF01_AE patients who were infected through blood transmission ($p = 0.249$). The CRF01_AE group was associated with a higher viral load in patients who were infected through sexual transmission (homosexual contact and heterosexual contact) ($p = 0.0007$ and $p = 0.0044$, respectively); however, the viral load was not higher in the patients infected through blood transmission ($p = 0.66$) (Figure 7-B).

**Time trends in TDR**

The overall TDR rate in this population was 4.4% (16 of 364 patients) between 2003 and 2013. To assess the changes of the

---

**Figure 6.** The proportion of various routes of HIV transmission in Shaanxi province during four time periods: 2003–2005; 2006–2008; 2009–2011; 2012–2013.

doi:10.1371/journal.pone.0109821.g006

**Figure 7.** The levels of CD4+ T cell count and viral load in CRF01_AE, non-CRF01_AE infected patients through different transmission routes. A, The levels of CD4+ T cell count in CRF01_AE and non-CRF01_AE infected patients through different transmission routes. A low level baseline CD4+ T cell count was found among the CRF01_AE-infected persons compared with the non-CRF01_AE patients infected through sexual transmission; B, The levels of HIV viral load in CRF01_AE and non-CRF01_AE infected patients through different transmission routes. The CRF01_AE group was associated with a higher viral load in patients who were infected through sexual transmission (homosexual contact and heterosexual contact); however, the viral load was not higher in the patients infected through blood transmission ($p = 0.66$) (Figure 7-B).

The overall TDR rate in this population was 4.4% (16 of 364 patients) between 2003 and 2013. To assess the changes of the
TDR prevalence over time, the sequences were grouped into four sampling time periods (2003–05, 2006–08, 2009–11, and 2012–13), according to the year of HIV-1 diagnosis. The TDR prevalence to any antiretroviral class slightly increased from the first period, peaked in 2006–08 (5.56%), decreased afterwards, and became stable between 2009 and 2013 (P = 0.982). (Figure 8).

Genotypic Analysis of DR

The proportion of sequences with resistance to NRTIs, NNRTIs, and PIs was 2.2% (8/364), and 1.9% (7/364), and 0.5% (2/364), respectively. When comparing resistance by drug class, dual class resistance was observed in only 1 of the 364 cases (0.27%), and none of the patients presented triple-class resistance. The PI-related mutations included I5V (0.27%, n = 1) and M46I (0.27%, n = 1). Eight NNRTI-related mutations were found, including T69D (0.33%, n = 2), L74I (0.27%, n = 1), M184V (0.33%, n = 2), L210W (0.27%, n = 1), T215S (0.27%, n = 1), and K219N (0.27%, n = 1). The 7 NNRTIs-related mutations were K101E (0.27%, n = 1), K103N (0.33%, n = 2), V106M (0.27%, n = 1), G190A (0.27%, n = 2), and G190E (0.27%, n = 1). The demographic characteristics of these 16 treatment-naive individuals are shown in Table 4. According to the interpretation of the Stanford HIV Drug Resistance Database, the 16 drug resistant viruses showed different levels of resistance to 11 antiretroviral drugs (Table 5). The transmitted drug resistance to EFV and NVP was significantly higher than that to the other drugs during the study period. Although 2 NNRTIs (ETR and RPV) and 1 NRTI (FTC) were not used in local patients, resistance to these agents is present, and this resistance might be because of cross-resistance.

The baseline characteristics, including age, gender, transmission route, CD4+ T-cell count, HIV-1 RNA viral load, and HIV-1 subtype, were included in the univariate logistic regression model to determine whether these factors were significantly associated with the presence of TDR (Table 6). The univariate model indicated that the only factor associated with the presence of TDR was the CD4+ T cell level (p = 0.007). The patients classified as “≤ 100 cells/μL” were more likely to harbor TDR than were the patients in the “101–350 cells/μL” (OR = 0.195, 95% CI: 0.053 to 0.719) and the “>350 cells/μL” CD4 (OR = 0.148, 95% CI: 0.032 to 0.686) groups. Because no other factors were found to be significantly associated with TDR, the planned multivariate regression model was not attempted.

Discussion

In the present study, we performed the first systematic study of HIV-1 molecular epidemiology and transmitted drug resistance in Shaanxi province. Using the phylogenetic reconstruction and recombination analysis, a total of eight HIV-1 subtypes, including B, C, G, and CRF01_AE, CRF07_BC, CRF08_BC, CRF55_01B, and URFs, were detected. A low level prevalence of HIV-1 TDR from 2003 to 2013 was identified. The TDR rate to any antiretroviral class slightly increased from the first period (2003–2005), peaked in 2006–08 (5.56%), then decreased afterwards and became stable between 2009 and 2013.

Shaanxi province had a population of 38.3 million in 2010 according to results of the sixth nationwide population census [23]. From 2011 to 2013, the cumulative number of reported HIV-1 and AIDS cases increased each year, with the figures for each year standing at 2098, 3094 and 4332, respectively [24]. A previous study demonstrated that between 2002 and 2003, Thai-B was the most common genotype, followed by CRF07_BC and CRF01_AE [25]. Our results are in agreement with these findings. In our study, the predominance of subtype B decreased significantly from 2003 to 2013, and the predominance of CRF01_AE increased from 9.76% to 43.03% in the last decade, which showed a distinct genotypic profile compared with other regions in China. For example, in the neighboring Henan province, up to 92% of HIV-1 subtypes were Thai-B [26], CRF08_BC was predominant and accounted for 59.8% of cases in Yunnan province [7], and CRF07_BC infection remained at a high prevalence in Xinjiang province [27].

The transmission routes of HIV-1 have changed dynamically over time. While illegal and unsanitary blood collection practices have been significantly reduced in Shaanxi, the number of persons infected with HIV through MSM dramatically increased, suggesting that the trend of HIV transmission is shifting from high-risk groups to the general population. MSM was the most prevalent mode of transmission in Shaanxi between 2012 and 2013. Nationwide epidemiologic surveys from the National Center for AIDS/STD Control and Prevention have revealed that among the newly diagnosed HIV-1 infections in 2013, 69.1% of cases could be attributed to heterosexual transmission, and 20.8% could be attributed to homosexual transmission [28]. Our finding is in accordance with Beijing [29], Shijiazhuang [30], and Harbin [31] surveillance, suggesting that MSM have become the most
| ID    | Gender | Age | Year Of Diagnosis | HIV-1 Subtype | Transmission route | CD4+ Count | Viral load | TDR mutation |
|-------|--------|-----|-------------------|---------------|-------------------|------------|------------|--------------|
| CXA-018 | Male   | 25  | 2003              | B             | blood             | 46         | 194        |              |
| CXA-119 | Male   | 39  | 2005              | B             | heterosexual      | 8          | 5.82E+03   | A71V         |
| CXA-095 | Male   | 56  | 2006              | B             | blood             | 34         | 1.41E+07   | A71T T69D    |
| CXA-140 | Female | 47  | 2007              | B             | heterosexual      | 13         | 2.25E+05   | A71V         |
| JY102108 | Male    | 45  | 2009             | CRF01_AE    | blood             | 27         | 9.88E+04   | V75L M184V T215A V106I |
| LWP103104 | Male    | 28  | 2009            | CRF01_AE    | homosexual        | 2          | 6.26E+05   | T69ADN       |
| CXY101017 | Male    | 46  | 2010            | CRF01_AE    | homosexual        | 31         | 9.89E+04   |              |
| JJ101013 | Male    | 31  | 2011            | CRF01_AE    | homosexual        | 390        | 1.01E+05   | M184V K103N V108I |
| WJC     | Male    | 42  | 2011            | CRF01_AE    | homosexual        | 35         | 3.70E+06   | L10V T215S   |
| kang-007 | Male    | 24  | 2012            | CRF01_AE    | homosexual        | 106        | 1.65E+05   | L74I         |
| kang-035 | Male    | 59  | 2012            | CRF01_AE    | heterosexual      | 17         | 1.44E+05   |              |
| kang-003a | Male   | 54  | 2013            | CRF01_AE    | heterosexual      | 29         | 5.63E+04   | T69N G190A   |
| kang-016a | Male   | 34  | 2013            | CRF01_AE    | homosexual        | 83         | 3.48E+05   | M46I V179D   |
| kang-119 | Male    | 22  | 2013            | CRF01_AE    | homosexual        | 175        | 1.20E+03   | K219N        |
| kang-128 | Male    | 23  | 2013            | CRF07_BC    | homosexual        | 362        | 4.23E+03   | L210W        |
| kang-218 | Male    | 28  | 2013            | CRF01_AE    | unknown           | 146        | 3.57E+04   | I85V         |

Bold letters: TDR mutations; PIs: protease inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non-nucleoside reverse transcriptase inhibitors; doi:10.1371/journal.pone.0109821.t004
Table 5. The levels of resistance to antiretroviral drugs from 16 individuals with TDR strains.

| NO. | ID      | Low-level resistance | Intermediate resistance | High-level resistance |
|-----|---------|-----------------------|-------------------------|----------------------|
| 1   | CXA-018 |                       |                         | EFV NVP              |
| 2   | CXA-119 |                       |                         | NVP                  |
| 3   | CXA-095 |                       |                         | DDI                  |
| 4   | CXA-140 |                       |                         |                     |
| 5   | JY102108| AZT TDF               | ABC D4T                 | 3TC FTC              |
| 6   | LPW103104|                     | DDI                     |                     |
| 7   | CYX101017|                     | ETR RPV                 | EFV NVP              |
| 8   | JJ101013| ABC                   |                         |                     |
| 9   | WJC     |                       |                         |                     |
| 10  | kang-007|                       |                         | ABC D4T              |
| 11  | kang-035| EFV ETR               | NVP                     |                     |
| 12  | kang-003a|                      | EFV                     | NVP                  |
| 13  | kang-016a|                      |                         |                     |
| 14  | kang-119|                       |                         |                     |
| 15  | kang-128| AZT D4T               |                         |                     |
| 16  | kang-218|                       |                         |                     |

The overall TDR rate in this population remained low (<5%) despite 10 years of the active introduction of ART in Shaanxi province, reflecting the high efficacy of HAART in the last decade. The TDR rate between 2012 and 2013 was 4.24%, which was similar to the results from another study in Yunnan (4.3%) [15]; however, this was lower than the results from studies in Henan (14.3%) [26] and Guangdong (6.7%) [36]. Similar studies performed in the United States and in European countries reported significantly higher prevalence (10.9% and 14.2%, respectively) of TDR [8–9]. Several factors might explain the observed discrepancy. Shaanxi has a shorter history of using ART compared with the developed areas or countries, where combination therapy has been common since the late 1990s (North America, Europe). Additionally, the high rates of acquired drug resistance could affect the prevalence of TDR. In addition, the transmitted drug resistance could be potentially underestimated due to the limited sample size.

A logistic regression analysis revealed that low CD4+ T cell counts (below 100 cells/µL) were closely correlated with the development of TDR. The median CD4 cell count was significantly lower among the patients with TDR compared with the patients without TDR. This finding is consistent with the results from the TREAT Asia and Hong Kong Studies [37–38], supporting the hypothesis that patients with advanced HIV-1 disease might be at greater risk of having HIV-1 TDR. Indeed, our study is a cross-sectional observation, it has several limits to identify the causal relationship between CD4 cell count and TDR. A further follow-up study will be needed to elaborate this relationship.

There are some limitations to the present study. First, HIV-1 TDR surveillance should be implemented in recently infected individuals, because over time, the mutations might revert to wild-type transmitted resistance variants (that might have reduced fitness capacity) or to the nonresistant genotypes, which could affect the accuracy of transmitted resistance surveillance [39]. Because recently infected persons are difficult to recruit and late diagnosis of HIV infection is common in China [40], our studies included individuals who might have been infected for a vulnerable population to HIV-1 infection in some northern metropolitan areas of China.

In this study, subtype B predominated among blood transmission, and CRF07_BC predominated among IDUs. CRF01_AE was dominant in the MSM group. These results are in agreement with other epidemiological findings from different studies [32–33] and suggest that the HIV-1 subtype was associated with the transmission route. We observed the highest viral diversity in MSM: five genotypes, consisting of four recombinants and subtype B, were detected in this population. Subtypes CRF55_01B and URFs (07BC/01AE) were first identified in Shaanxi. These results suggest that the coexistence of multiple HIV-1 genotypes may facilitate the generation of new recombination forms in MSM and make HIV-1 genetics intricate.

A recent study suggested that the CRF01_AE subtype is associated with higher viral load and faster progression from the estimated time of seroconversion to AIDS compared with non-CRF01_AE subtype [34]. Another retrospective study revealed that a low baseline CD4+ T cell count was found among the CRF01_AE subtype compared with the CRF07_BC subtype in MSM [35]. These findings suggest that the CRF01_AE subtype is associated with progression to AIDS and advanced immunosuppression. However, they did not address whether different risk populations are associated with different results. Our observation in patients infected through sexual transmission was in agreement with previous results; however, we did not observe this trend in patients infected by blood transmission, which suggests that the correlation between CRF01_AE and disease progression could be different in various risk populations. Because the number of IDUs is in our cohort was small, further studies will be performed to evaluate the influence of the HIV subtypes on HIV progression in IDU groups. Based on our results, we cannot get the conclusion that a lower CD4 cell count has a causal relationship with CRF01_AE as patients infected with a CRF01_AE subtype could have been diagnosed during a later stage of their infection than those infected with non-CRF01_AE subtype.

The overall TDR rate in this population remained low (<5%) despite 10 years of the active introduction of ART in Shaanxi province, reflecting the high efficacy of HAART in the last decade. The TDR rate between 2012 and 2013 was 4.24%, which was similar to the results from another study in Yunnan (4.3%) [15]; however, this was lower than the results from studies in Henan (14.3%) [26] and Guangdong (6.7%) [36]. Similar studies performed in the United States and in European countries reported significantly higher prevalence (10.9% and 14.2%, respectively) of TDR [8–9]. Several factors might explain the observed discrepancy. Shaanxi has a shorter history of using ART compared with the developed areas or countries, where combination therapy has been common since the late 1990s (North America, Europe). Additionally, the high rates of acquired drug resistance could affect the prevalence of TDR. In addition, the transmitted drug resistance could be potentially underestimated due to the limited sample size.

A logistic regression analysis revealed that low CD4+ T cell counts (below 100 cells/µL) were closely correlated with the development of TDR. The median CD4 cell count was significantly lower among the patients with TDR compared with the patients without TDR. This finding is consistent with the results from the TREAT Asia and Hong Kong Studies [37–38], supporting the hypothesis that patients with advanced HIV-1 disease might be at greater risk of having HIV-1 TDR. Indeed, our study is a cross-sectional observation, it has several limits to identify the causal relationship between CD4 cell count and TDR. A further follow-up study will be needed to elaborate this relationship.

There are some limitations to the present study. First, HIV-1 TDR surveillance should be implemented in recently infected individuals, because over time, the mutations might revert to wild-type transmitted resistance variants (that might have reduced fitness capacity) or to the nonresistant genotypes, which could affect the accuracy of transmitted resistance surveillance [39]. Because recently infected persons are difficult to recruit and late diagnosis of HIV infection is common in China [40], our studies included individuals who might have been infected for a

Table 5. The levels of resistance to antiretroviral drugs from 16 individuals with TDR strains.

| NO. | ID     | Low-level resistance | Intermediate resistance | High-level resistance |
|-----|--------|----------------------|-------------------------|----------------------|
| 1   | CXA-018|                      |                         | EFV NVP              |
| 2   | CXA-119|                      |                         | NVP                  |
| 3   | CXA-095|                      |                         | DDI                  |
| 4   | CXA-140|                      |                         |                     |
| 5   | JY102108|                     | AZT TDF               | ABC D4T             |
| 6   | LPW103104|                    | DDI                     |                     |
| 7   | CYX101017|                    | ETR RPV                | EFV NVP             |
| 8   | JJ101013|                     | ABC                     |                     |
| 9   | WJC    |                      |                         |                     |
| 10  | kang-007|                     |                         | ABC D4T             |
| 11  | kang-035|                     | EFV ETR                | NVP                  |
| 12  | kang-003a|                    | EFV                     | NVP                  |
| 13  | kang-016a|                    |                         |                     |
| 14  | kang-119|                     |                         |                     |
| 15  | kang-128|                     | AZT D4T                |                     |
| 16  | kang-218|                     |                         |                     |

The overall TDR rate in this population remained low (<5%) despite 10 years of the active introduction of ART in Shaanxi province, reflecting the high efficacy of HAART in the last decade. The TDR rate between 2012 and 2013 was 4.24%, which was similar to the results from another study in Yunnan (4.3%) [15]; however, this was lower than the results from studies in Henan (14.3%) [26] and Guangdong (6.7%) [36]. Similar studies performed in the United States and in European countries reported significantly higher prevalence (10.9% and 14.2%, respectively) of TDR [8–9]. Several factors might explain the observed discrepancy. Shaanxi has a shorter history of using ART compared with the developed areas or countries, where combination therapy has been common since the late 1990s (North America, Europe). Additionally, the high rates of acquired drug resistance could affect the prevalence of TDR. In addition, the transmitted drug resistance could be potentially underestimated due to the limited sample size.

A logistic regression analysis revealed that low CD4+ T cell counts (below 100 cells/µL) were closely correlated with the development of TDR. The median CD4 cell count was significantly lower among the patients with TDR compared with the patients without TDR. This finding is consistent with the results from the TREAT Asia and Hong Kong Studies [37–38], supporting the hypothesis that patients with advanced HIV-1 disease might be at greater risk of having HIV-1 TDR. Indeed, our study is a cross-sectional observation, it has several limits to identify the causal relationship between CD4 cell count and TDR. A further follow-up study will be needed to elaborate this relationship.

There are some limitations to the present study. First, HIV-1 TDR surveillance should be implemented in recently infected individuals, because over time, the mutations might revert to wild-type transmitted resistance variants (that might have reduced fitness capacity) or to the nonresistant genotypes, which could affect the accuracy of transmitted resistance surveillance [39]. Because recently infected persons are difficult to recruit and late diagnosis of HIV infection is common in China [40], our studies included individuals who might have been infected for a
considerably longer time and are considered to be “chronically infected”. The results might be biased by the high proportion of patients with low CD4+ T cell (≤200 cells/μL). The degree of this bias will be affected by the time between HIV-1 infection and diagnosis, which may have changed over time. Second, our testing was based on population sequencing and might have missed minority variants at levels 20–25% of the virus population [41].

Our study provided a timely update on the molecular epidemiology of HIV-1 among the various risk populations in Shaanxi province. The characteristics of transmitted drug resistance were described here for the first time. These findings provide important information for improving clinical practices and for policy-making.

Acknowledgments
The authors thank their colleagues in the Department of Infectious Diseases of Tang du hospital for their efforts in patient recruitment and for providing blood samples. The authors appreciate the kind assistance provided by Bing Chen (Beijing HUIHUACHEN science & technology Co., Ltd).

Author Contributions
Conceived and designed the experiments: KZ WK YS. Performed the experiments: KZ YL Qing Liu WJ CW ZY NY. Analyzed the data: KZ Qingquan Liu ZG XL. Contributed reagents/materials/analysis tools: YL ZG Qing Liu YZ. Wrote the paper: KZ. Reviewed the manuscript: WK YS.

References
1. UNAIDS website. UNAIDS report on the global AIDS epidemic. Available: http://www.unaids.org/. Accessed 2013 Dec.
2. Hamimi C, Pancino G, Barre-Sinoussi F, Saez-Cirion A (2013) Will it be possible to live without antiretroviral therapy? Curr Opin HIV AIDS 8: 196–203.
3. Chun TW, Fauci AS (2012) HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26: 1261–1268.
4. Baden LR, Dolin R (2012) The road to an effective HIV vaccine. N Engl J Med 366: 1343–1344.
5. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881–1893.
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220.

Table 6. Univariate analysis of factors associated with the presence of HIV-1 TDR.

| Factors                      | OR     | 95% CI          | P    | Global P |
|------------------------------|--------|-----------------|------|----------|
| Gender                       |        |                 |      |          |
| Male                         | 1      |                 | 0.275|          |
| Female                       | 0.321  | 0.042-2.476     | 0.275|          |
| Age years                    |        |                 | 0.495|          |
| 25–35                        | 1      |                 |      |          |
| 26–35                        | 0.553  | 0.134-2.281     | 0.412|          |
| 36–45                        | 0.593  | 0.128-2.740     | 0.503|          |
| >45                          | 1.417  | 0.364-5.519     | 0.616|          |
| Transmission route           |        |                 | 0.980|          |
| Heterosexual contact         | 1      |                 |      |          |
| Homosexual contact           | 0.828  | 0.256-2.681     | 0.753|          |
| Blood transfusion            | 1.293  | 0.296-5.650     | 0.732|          |
| IDU                          | 0.000  | 0.000           | 0.999|          |
| Unknown                      | 1.141  | 0.125-10.382    | 0.907|          |
| CD4+ T cell (cells/μL)       |        |                 | 0.007|          |
| ≤100                         | 1      |                 |      |          |
| 101–350                      | 0.195  | 0.053-0.719     | 0.014|          |
| >350                         | 0.148  | 0.032-0.686     | 0.015|          |
| HIV RNA (copies/ml)          |        |                 | 0.974|          |
| ≤1000                        | 1      |                 |      |          |
| 1001–10000                   | 2.020  | 0.201-20.269    | 0.550|          |
| 10001–100000                 | 1.361  | 0.147-12.613    | 0.786|          |
| 1000001–1000000              | 1.636  | 0.190-14.072    | 0.654|          |
| >100000000                   | 1.784  | 0.355-20.586    | 0.643|          |
| HIV-1 subtype                |        |                 | 0.118|          |
| CRF01_AE                     | 1      |                 |      |          |
| CRF07_BC                     | 8.872  | 1.119-70.347    | 0.039|          |
| B                            | 6.860  | 0.787-59.783    | 0.081|          |

Cl, confidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0109821.t006
22. Han X, An M, Zhang W, Cai W, Chen X, et al. (2013) Genome Sequences of a
21. Saravanan S, Vidya M, Balakrishnan P, Kumarasamy N, Solomon SS, et al. (2013) Transmitted drug resistance in the CAFAR network of integrated clinical systems cohort: prevalence and effects on pre-treatment CD4 and viral load. PLoS One 6: e21189.
20. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, et al. (1999) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947–2948.
19. Siepel AC, Halpern AL, Macken C, Korber BT (1995) A computer program for evolutionary pathways of transmitted drug-resistant HIV-1 across the world. AIDS Rev 14: 17–27.
18. Hall BG (2013) Building phylogenetic trees from molecular data with MEGA. Mol Biol Evol 30: 1229–1235.
17. Larkin MA, Blackshields G, Brown NP, Chenna R, McGlinn PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947–2948.
16. Bennett DE, Camacho RJ, Oteola D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. PLoS One 4: e7424.
15. Chen M, Ma Y, Duan S, Xing H, Yao S, et al. (2012) Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. BMC Infect Dis 12: 382.
14. Huang D, Zhuang Y, Zhai S, Song Y, Liu Q, et al. (2010) HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China. Diagn Microbiol Infect Dis 68: 208–213.
13. Yang J, Xing H, Niu J, Liao L, Ruan Y, et al. (2013) The emergence of HIV-1 primary drug resistance genotypes among treatment-naive men who have sex with men in high-prevalence areas in China. Arch Virol 158: 839–844.
12. Zeng P, Liu Y, He M, Gao Z, Zhou Y, et al. (2013) HIV-1 genotypic diversity and prevalence of drug resistance among treatment naive HIV-infected individuals in Chengdu of China. Virus Genes 47: 408–413.
11. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of different distribution of HIV-1 drug resistance among newly HIV-infected individuals in Shaanxi. 2013. Available: http://www.sxhealth.gov.cn/newstyle.gov.cn/news. Accessed 2010 Dec.
10. World Health Organization website. WHO Drug Resistance Report. Available: http://www.who.int/hiv/pub/drugresistance/report2012/en/. Accessed 2012 Dec.
9. Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, et al. (2011) HIV-1 drug resistance and thumb subdomain polymorphisms among newly HIV type 1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China. AIDS Res Hum Retroviruses 28: 1723–1728.
8. Frentz D, Boucher CA, van de Vijver DA (2012) Temporal changes in the dynamics of human immunodeficiency virus type 1 CRF07_BC in Xinjiang, China. J Gen Virol 90: 1577–1761.
7. Li L, Sun G, Liang S, Li J, Li T, et al. (2013) Different distribution of HIV-1 subtypes and drug resistance were found among treatment-naive individuals in Henan, Guangxi, and Yunnan province of China. PLoS One 8: e75777.
6. Ruan Y, Qin G, Liu S, Qian H, Zhang L, et al. (2005) HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr 39: 459–463.
5. Pan XH, Zhang JF, Yao YF, Xia Y, Yang JZ, et al. (2010) [Subtype and transmission of HIV in both injection infected spousal in Zhejiang province]. Zhonghua Lui Xing Bing Xue Za Zhi 31: 638–641.
4. LI Y, Han Y, Xie J, Gu L, Li W, et al. (2014) CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS 28: 521–530.
3. Li X, Xue Y, Zhou L, Lin Y, Yu X, et al. (2014) Evidence That HIV-1 CRF01_AE Is Associated with Low CD4+ T Cell Count and CXCR4 Co-Receptor Usage in Recently Infected Young Men Who Have Sex with Men (MSM) in Shanghai, China. PLoS One 9: e98462.
2. Yang C, Liu S, Zhang T, Hou Y, Liu X, et al. (2012) Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV-1 type 1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China. AIDS Res Hum Retroviruses 28: 1723–1728.
1. Shao B, Li Y, Yu L, Wang K, Chang M, et al. (2014) The HIV/AIDS epidemic characteristics in a northeast province of China-men who have sex with men have made a tremendous contribution to the growth of the HIV epidemic. J Infect 68: 273–280.